Your browser doesn't support javascript.
loading
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Ermisch, Michael; Bucsics, Anna; Vella Bonanno, Patricia; Arickx, Francis; Bybau, Alexander; Bochenek, Tomasz; van de Casteele, Marc; Diogene, Eduardo; Fürst, Jurij; Garuoliene, Kristina; van der Graaff, Martin; Gulbinovic, Jolanta; Haycox, Alan; Jones, Jan; Joppi, Roberta; Laius, Ott; Langner, Irene; Martin, Antony P; Markovic-Pekovic, Vanda; McCullagh, Laura; Magnusson, Einar; Nilsen, Ellen; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Sauermann, Robert; Schuurman, Ad; Ramos, Ricardo; Vlahovic-Palcevski, Vera; Zara, Corinne; Godman, Brian.
Affiliation
  • Ermisch M; Pharmaceuticals Department, National Association of Statutory Health Insurance Funds Berlin, Germany.
  • Bucsics A; Department of Finance, University of Vienna Vienna, Austria.
  • Vella Bonanno P; Independent Pharmaceutical Consultant Mellieha, Malta.
  • Arickx F; National Institute for Health and Disability Insurance Bruxelles, Belgium.
  • Bybau A; Zilveren Kruis Achmea Leiden, Netherlands.
  • Bochenek T; Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College Krakow, Poland.
  • van de Casteele M; National Institute for Health and Disability Insurance Bruxelles, Belgium.
  • Diogene E; Clinical Pharmacology Service, Vall d'Hebron University Hospital, Fundació Institut Català de Farmacologia Barcelona, Spain.
  • Fürst J; Medicinal Products Department, Health Insurance Institute of Slovenia Ljubljana, Slovenia.
  • Garuoliene K; Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Vilnius UniversityVilnius, Lithuania; Medicines Reimbursement Department, National Health Insurance FundVilnius, Lithuania.
  • van der Graaff M; National Health Care Institute Diemen, Netherlands.
  • Gulbinovic J; Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Vilnius UniversityVilnius, Lithuania; State Medicines Control AgencyVilnius, Lithuania.
  • Haycox A; Health Economics Centre, University of Liverpool Management School Liverpool, UK.
  • Jones J; Scottish Medicines Consortium Glasgow, UK.
  • Joppi R; Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona Verona, Italy.
  • Laius O; State Agency of Medicines Tartu, Estonia.
  • Langner I; Wissenschaftliches Institut der AOK (WIdO) Berlin, Germany.
  • Martin AP; Health Economics Centre, University of Liverpool Management School Liverpool, UK.
  • Markovic-Pekovic V; Ministry of Health and Social WelfareBanja Luka, Bosnia and Herzegovina; Department of Social Pharmacy, Medical Faculty, University Banja LukaBanja Luka, Bosnia and Herzegovina.
  • McCullagh L; Pharmacoeconomics and Health Technology Assessment, Department of Pharmacology and Therapeutics, Trinity College Dublin, Ireland.
  • Magnusson E; Department of Health Services, Ministry of Health Reykjavík, Iceland.
  • Nilsen E; Norweigian Directorate for Health Oslo, Norway.
  • Selke G; Wissenschaftliches Institut der AOK (WIdO) Berlin, Germany.
  • Sermet C; Institut de Recherche et Documentation en Economie de la Santé (IRDES) Paris, France.
  • Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven Leuven, Belgium.
  • Sauermann R; Department of Pharmaceutical Affairs, Main Association of Austrian Social Insurance Institutions Vienna, Austria.
  • Schuurman A; National Health Care Institute Diemen, Netherlands.
  • Ramos R; Health Technology Assessment, Prices and Reimbursement Department, INFARMED - National Authority of Medicines and Health Products, I. P., Parque de Saúde de Lisboa Lisbon, Portugal.
  • Vlahovic-Palcevski V; Department of Clinical Pharmacology, University Hospital Rijeka, Croatia.
  • Zara C; Barcelona Health Region, Catalan Health Service Barcelona, Spain.
  • Godman B; Health Economics Centre, University of Liverpool Management SchoolLiverpool, UK; Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of StrathclydeGlasgow, UK; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Insti
Front Pharmacol ; 7: 305, 2016.
Article de En | MEDLINE | ID: mdl-27733828
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Health_technology_assessment Langue: En Journal: Front Pharmacol Année: 2016 Type de document: Article Pays d'affiliation: Allemagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Health_technology_assessment Langue: En Journal: Front Pharmacol Année: 2016 Type de document: Article Pays d'affiliation: Allemagne